BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 29917295)

  • 41. Down-regulation of histone deacetylase 4, -5 and -6 as a mechanism of synergistic enhancement of apoptosis in human lung cancer cells treated with the combination of a synthetic retinoid, Am80 and green tea catechin.
    Oya Y; Mondal A; Rawangkan A; Umsumarng S; Iida K; Watanabe T; Kanno M; Suzuki K; Li Z; Kagechika H; Shudo K; Fujiki H; Suganuma M
    J Nutr Biochem; 2017 Apr; 42():7-16. PubMed ID: 28103535
    [TBL] [Abstract][Full Text] [Related]  

  • 42. ACY 1215, a histone deacetylase 6 inhibitor, inhibits cancer cell growth in melanoma.
    Wang F; Zhong BW; Zhao ZR
    J Biol Regul Homeost Agents; 2018; 32(4):851-858. PubMed ID: 30043566
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The selective HDAC6 inhibitor Nexturastat A induces apoptosis, overcomes drug resistance and inhibits tumor growth in multiple myeloma.
    Sun X; Xie Y; Sun X; Yao Y; Li H; Li Z; Yao R; Xu K
    Biosci Rep; 2019 Mar; 39(3):. PubMed ID: 30782785
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Histone deacetylase 6 inhibitor tubastatin A attenuates angiotensin II-induced hypertension by preventing cystathionine γ-lyase protein degradation.
    Chi Z; Byeon HE; Seo E; Nguyen QT; Lee W; Jeong Y; Choi J; Pandey D; Berkowitz DE; Kim JH; Lee SY
    Pharmacol Res; 2019 Aug; 146():104281. PubMed ID: 31125601
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Different Schedule-Dependent Effects of Epigenetic Modifiers on Cytotoxicity by Anticancer Drugs in Colorectal Cancer Cells.
    Hosokawa M; Tanaka S; Ueda K; Iwakawa S
    Biol Pharm Bull; 2017 Dec; 40(12):2199-2204. PubMed ID: 28954936
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Design and biological evaluation of tetrahydro-β-carboline derivatives as highly potent histone deacetylase 6 (HDAC6) inhibitors.
    Leonhardt M; Sellmer A; Krämer OH; Dove S; Elz S; Kraus B; Beyer M; Mahboobi S
    Eur J Med Chem; 2018 May; 152():329-357. PubMed ID: 29738953
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Discovery of Novel Histone Deacetylase 6 (HDAC6) Inhibitors with Enhanced Antitumor Immunity of Anti-PD-L1 Immunotherapy in Melanoma.
    Peng X; Li L; Chen J; Ren Y; Liu J; Yu Z; Cao H; Chen J
    J Med Chem; 2022 Feb; 65(3):2434-2457. PubMed ID: 35043615
    [TBL] [Abstract][Full Text] [Related]  

  • 48. HDAC8-Selective Inhibition by PCI-34051 Enhances the Anticancer Effects of ACY-241 in Ovarian Cancer Cells.
    Kim JY; Han SY; Yoo J; Kim GW; Jeon YH; Lee SW; Park J; Kwon SH
    Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955780
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Histone deacetylase inhibitors synergistically potentiate death receptor 4-mediated apoptotic cell death of human T-cell acute lymphoblastic leukemia cells.
    Sung ES; Kim A; Park JS; Chung J; Kwon MH; Kim YS
    Apoptosis; 2010 Oct; 15(10):1256-69. PubMed ID: 20582477
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The HDAC6 Inhibitor Tubacin Induces Release of CD133
    Chao OS; Chang TC; Di Bella MA; Alessandro R; Anzanello F; Rappa G; Goodman OB; Lorico A
    J Cell Biochem; 2017 Dec; 118(12):4414-4424. PubMed ID: 28452069
    [TBL] [Abstract][Full Text] [Related]  

  • 51. HDAC6 inhibition induces the failure of mouse early embryonic development.
    Wang H; Ling L; Ai L; Bai L
    J Cell Physiol; 2019 Jun; 234(6):8752-8759. PubMed ID: 30370558
    [TBL] [Abstract][Full Text] [Related]  

  • 52. High-selective HDAC6 inhibitor promotes HDAC6 degradation following autophagy modulation and enhanced antitumor immunity in glioblastoma.
    Liu JR; Yu CW; Hung PY; Hsin LW; Chern JW
    Biochem Pharmacol; 2019 May; 163():458-471. PubMed ID: 30885763
    [TBL] [Abstract][Full Text] [Related]  

  • 53. HDAC6 inhibition by tubastatin A is protective against oxidative stress in a photoreceptor cell line and restores visual function in a zebrafish model of inherited blindness.
    Leyk J; Daly C; Janssen-Bienhold U; Kennedy BN; Richter-Landsberg C
    Cell Death Dis; 2017 Aug; 8(8):e3028. PubMed ID: 29048427
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Design, synthesis and biological evaluation of novel hydroxamic acid based histone deacetylase 6 selective inhibitors bearing phenylpyrazol scaffold as surface recognition motif.
    Yang J; Cheng G; Xu Q; Luan S; Wang S; Liu D; Zhao L
    Bioorg Med Chem; 2018 May; 26(8):1418-1425. PubMed ID: 29500130
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The anticancer effects of MPT0G211, a novel HDAC6 inhibitor, combined with chemotherapeutic agents in human acute leukemia cells.
    Tu HJ; Lin YJ; Chao MW; Sung TY; Wu YW; Chen YY; Lin MH; Liou JP; Pan SL; Yang CR
    Clin Epigenetics; 2018 Dec; 10(1):162. PubMed ID: 30594243
    [TBL] [Abstract][Full Text] [Related]  

  • 56. PTG-0861: A novel HDAC6-selective inhibitor as a therapeutic strategy in acute myeloid leukaemia.
    Gawel JM; Shouksmith AE; Raouf YS; Nawar N; Toutah K; Bukhari S; Manaswiyoungkul P; Olaoye OO; Israelian J; Radu TB; Cabral AD; Sina D; Sedighi A; de Araujo ED; Gunning PT
    Eur J Med Chem; 2020 Sep; 201():112411. PubMed ID: 32615502
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Tubastatin A, an inhibitor of HDAC6, enhances temozolomide‑induced apoptosis and reverses the malignant phenotype of glioblastoma cells.
    Urdiciain A; Erausquin E; Meléndez B; Rey JA; Idoate MA; Castresana JS
    Int J Oncol; 2019 May; 54(5):1797-1808. PubMed ID: 30864703
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Preferential HDAC6 inhibitors derived from HPOB exhibit synergistic antileukemia activity in combination with decitabine.
    Tretbar M; Schliehe-Diecks J; von Bredow L; Tan K; Roatsch M; Tu JW; Kemkes M; Sönnichsen M; Schöler A; Borkhardt A; Bhatia S; Hansen FK
    Eur J Med Chem; 2024 Jun; 272():116447. PubMed ID: 38714044
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Blockade of histone deacetylase 6 protects against cisplatin-induced acute kidney injury.
    Tang J; Shi Y; Liu N; Xu L; Zang X; Li P; Zhang J; Zheng X; Qiu A; Zhuang S
    Clin Sci (Lond); 2018 Feb; 132(3):339-359. PubMed ID: 29358506
    [TBL] [Abstract][Full Text] [Related]  

  • 60. HDAC inhibitors, MS275 and SBHA, enhances cytotoxicity induced by oxaliplatin in the colorectal cancer cell lines.
    Flis S; Gnyszka A; Spławiński J
    Biochem Biophys Res Commun; 2009 Sep; 387(2):336-41. PubMed ID: 19596269
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.